Danish Study Group on Verapamil in MI - DAVIT II


Verapamil versus placebo after acute MI.


To evaluate the effect on total mortality and major cardiac events of verapamil started in the second week after MI.

Study Design

Study Design:

Patients Screened: Not reported
Patients Enrolled: 1975
NYHA Class: At 12 month follow-up: Class I: 75.8%, Class II: 22.7%, Class III-IV: 1.5%
Mean Follow Up: average 16 months
Mean Patient Age: = 65 years: 34%
Female: 20%
Mean Ejection Fraction: Not evaluated

Patient Populations:

<75 years of age enrolled 7–15 days after proven MI


SBP <90 mm Hg, second- or third-degree heart block at 3 days, heart failure not stabilizing on furosemide ≤160 mg/day, treatment with β-blockers or calcium antagonists due to angina pectoris, arrhythmias, hypertension, postoperative infarction, and significant valvular or congenital heart disease.

Primary Endpoints:

Death and reinfarction

Secondary Endpoints:

Sudden death, cardiac death, and cardiac events (cardiac death or reinfarction)

Drug/Procedures Used:

Verapamil 120 mg three times daily (once or twice daily dosing allowed in cases of adverse drug reactions), or placebo.

Principal Findings:

The verapamil group had a 17% lower incidence of death and reinfarction (18.0% vs. 21. 6%; p = 0.03). There was also a nonsignificant 20% lower mortality (11.1% vs. 13.8%; p = 0.11) with a significant mortality reduction in the verapamil-treated patients without congestive heart failure (7.7% vs. 11.8%; p = 0.02). In patients with CHF, there was a similar incidence of primary events (17.9% vs. 17.5%).


Verapamil therapy after acute MI was associated with a reduction in death and reinfarction but only patients without heart failure.


Am J Cardiol 1990;66:779–785.

Clinical Topics: Heart Failure and Cardiomyopathies, Acute Heart Failure

Keywords: Drug-Related Side Effects and Adverse Reactions, Heart Failure, Coronary Disease, Verapamil, Calcium Channel Blockers

< Back to Listings